Tinaghanao, Addi .

HRN: 26-72-52  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/18/2025
CO-AMOXICLAV 625MG (TAB)
02/18/2025
02/24/2025
PO
625mg
Once Daily
Tonsillopharyngitis
Waiting Final Action 
02/21/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
02/21/2025
02/28/2025
IV
1.5gms
Q8
Acute Tonsillopharyngitis
Waiting Final Action 
02/21/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/21/2025
02/28/2025
IV
4.5gms
Q6
Severe Neutropenia
Checking Final Appropriateness 
02/21/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/21/2025
02/28/2025
IV
500mg
Q8
Abdominal Infections
Checking Final Appropriateness 
02/24/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/24/2025
03/03/2025
IV
500mg
Q8
Amoebiasis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: